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Massively parallel sequencing technology has recently identified recurrent somatic mutations in SETBP1 gene in atypical chronic myeloid leukemia.
1 SETBP1 is located on chromosome 18q21.1 and encodes SET binding protein 1. Identical nucleotide alterations resulting in protein changes affecting predominantly residues 858-871 have been reported in Schinzel-Giedion syndrome, a rare congenital disorder, characterized by severe mental retardation, distinctive facial features and multiple congenital malformations. 2 The mutations target the substrate recognition domain of the E3 ubiquitin ligase and may affect ubiquitin binding 1 A functional impact of SETBP1 mutations is highly likely as cell lines transfected with mutated SETBP1 exhibit increased SETBP1 protein levels, enhanced inhibition of PP2A activity and higher proliferation rates.
1 SETBP1 has been identified as a rare chromosomal translocation partner in lymphoid and myeloid acute leukemias. 3, 4 Its overexpression, which is associated also with aberrations of chromosome 7 and poor prognosis in acute myeloid leukemias (AML), 4 was shown to confer self-renewal capabilities to murine myeloid progenitors. 5 To date, little is known regarding prevalence, clinical and prognostic value of SETBP1 mutations in other myeloid malignancies. We therefore investigated the mutational hotspot of SETBP1 in a large cohort of 195 chronic myelomonocytic leukemia (CMML), 222 myelodysplastic syndromes (MDS) and 241 secondary AML (sAML) patients by Sanger sequencing. CMML and MDS patient samples were collected in noninterventional studies (MYELOMONO and MAD-06, respectively) by the Groupe Francophone des Myelodysplasies (GFM), and sAML patient samples were collected at enrollment in multicenter clinical trials by the Groupe Ouest-Est d'é tude des Leucé mies Aiguë s et Autres Maladies du Sang (GOELAMS). Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Both GFM and GOELAMS studies were approved by the Paris Center ethics committee. For all three cohorts, patient characteristics and treatment details have been published earlier. [6] [7] [8] Primer sequences were: 1 F 5 0 -CATCAGTGCTCTTCCAACCA-3 0 and 1R 5 0 -TCCGTTTCCTCTTGTGCTTT-3 0 . Liquid-culture of CD34 þ -sorted single cells from two CMML patients was performed in minimum essential medium-alpha milieu with 10% fetal bovine serum and recombinant human cytokines: stem cell factor (50 ng/ml), FLT3-ligand (50 ng/ml), pegylated thrombopoietin (10 ng/ml), interleukin-3 (10 ng/ml), interleukin-6 (10 ng/ml), granulocytemacrophage colony-stimulating factor (5 ng/ml), erythropoietin (1 IU/ml) and granulocyte colony-stimulating factor (10 ng/ml). 9 Statistical analyses were performed with R 2.14.1 or STATA v12 (STATA Corporation, College Station, TX, USA).
Point mutations in SETBP1 were detected in 21 out of 658 (3.2%) investigated patients (Supplementary Table 1 ). All but one were heterozygous missense mutations. Although SETBP1 mutations were rare in sAML (4/241 ¼ 1.7%) and MDS (5/222 ¼ 2.2%) patients, a higher frequency was detected in the CMML cohort (12/195 ¼ 6.2%). Mutations mainly affected residues 858-871, except a single case of D908N substitution. Among the 21 patients, nine harbored a D868N, three a G870S, two a G870D, two an E858K substitution, while only single cases showed a D868H, S869G, S869R, I871S or D908N substitution. The somatic nature of these mutations was confirmed by sequencing nontumoral DNA from CD3 þ cells in three patients (2xD868N, 1xS869G). Among the four sAML patients with SETBP1 mutation, three progressed to AML from an antecedent MDS, and the last one from a myeloproliferative neoplasm. Of note, three of the four patients showed aberrations involving chromosome 7, and two an inversion of chromosome 3 known to be associated with a poor outcome in AML. 10 Among the five SETBP1-mutated MDS patients, three were classified as RAEB-1/2, one as RA and one as RCMD. All of them were classified in IPSS low-or intermediate-1-risk groups. Although cytogenetics revealed a normal karyotype in two cases, one deletion of chromosome 7q and one del 11 (q13) were found. Most frequent concomitant mutations were ASXL1 and TET2 in two patients each. Follow-up data were available for four of the five SETBP1-mutated MDS patients. Two patients died from AML transformation and two were still alive 2 and 4 years after MDS diagnosis. The low number of SETBP1-mutated sAML and MDS cases precluded survival analysis in these two cohorts.
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Regarding the 195 CMML patients, the comparison of baseline characteristics such as age, sex, WHO category and karyotype did not reveal differences between SETBP1-mutated and wild-type patients. SETBP1-mutated CMML patients had higher white blood cell (WBC) counts (median: 16.5 Â 10 9 /l vs 11.3 Â 10 9 /l in SETBP1-wild-type patients; P ¼ 0.03) and more frequent extramedullary disease (45 vs 17%; P ¼ 0.03). SETBP1 mutations were more frequent in ASXL1-mutated CMML patients (67 vs 33%; P ¼ 0.03), and less frequent in TET2-mutated patients (25 vs 64%; P ¼ 0.01), suggesting distinct co-operative molecular events in SETBP1-mutated CMML (Figure 1a ). Follow-up data were available for all 195 CMML patients (median 31. Table 2) . Our results are in line with the recently reported clinical phenotype of SETBP1 mutations in atypical CML, in which these mutations were associated with elevated WBC counts, less often found in TET2-mutated cases, and associated with an adverse prognosis. 1 To compare the timing of SETBP1 mutations with other gene mutations during CMML evolution, we genotyped single-cell colonies derived from different CD34 þ fractions by direct sequencing, as reported. 9 For patient UPN no. 498, bone marrow CD34 þ progenitor fractions were sorted according to the following immunophenotypes:
þ (granulocyte-monocyte progenitors, GMP). Sorted cells were seeded at one cell per well in 96-well plates. All four potential driver mutations (ASXL1, SETBP1, SRSF2 and ZRSR2) occurred very early during differentiation, as they were detected in colonies from the HSC fraction. The D868N SETBP1 mutation occurred after ASXL1 and ZRSR2, but before the SRSF2 mutation (Figures 2a and b) . These data illustrate the dynamics of subclones during myeloid differentiation as the triple-mutated ASXL1/ZRSR2/SETBP1 clone was more frequent in CMP and GMP than in HSC, suggesting that the SETBP1 mutation provides an advantage to the clone during myeloid differentiation (Figures 2a  and b) . For patient UPN no. 638, sorted peripheral blood CD34 þ
CD38
À cells were cloned at one cell per well in 96-well plates at three different time points: CMML diagnosis, sAML progression after six cycles of azacitidine treatment, and after 6 months of palliative care with hydroxyurea. Again, all five potential driver mutations (ASXL1, CBL, SETBP1, SF3B1 and SRSF2) could be identified in colonies derived from these CD34 þ CD38
À multipotent progenitors (Figures 2c and d) . These data show a linear acquisition of these five mutations and are in line with an early clonal dominance reported for CMML and MDS. 9, 11, 12 The D868N SETBP1 mutation occurred together with the ASXL1 alteration after the SF3B1, CBL and SRSF2 mutations. Although this multiple mutated clone was found as a subclone during the CMML phase, it expanded and became the predominant clone during progression to AML (Figures 2c and d) .
In summary, SETBP1 mutations observed in about 6% of patients with a CMML are likely associated with ASXL1 mutations, higher WBC counts, extramedullary disease and poor prognosis. They occur at later stages of disease evolution and might influence the clinical course of the disease rather than its initiation. In MDS and sAML, the rare mutations in SETBP1 might be associated with distinct cytogenetic aberrations involving chromosomes 3 and 7.
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